

HEP C U Later

Wessex Clinical Van Report
from Quarter 3 of 2021/22

High Intensity Test and Treat (HITT) Events

Southampton Bassil Pharmacy, November 4th 2021

Before holding the testing event, a focused piece of work was done with Change Grow Live (CGL) to identify the highest footfall pharmacy which could accommodate the van being parked nearby. Bassil Pharmacy was identified with a potential footfall of 69 patients and at least 7 known untreated RNA+, some of whom have been positive for over 15 years.

Before the event several stakeholder planning meetings were held and CGL sent out letters to all patients registered at Bassil Pharmacy, informing them of the event and offering a £5 incentive for testing.



| | Number | Notes |
|------------------|--------|---|
| Number seen | 35 | 3 people did not need testing |
| Antibody tests | 20 | 18 negative 2 positive |
| Cepheid tests | 12 | 5 negative 7 positive (4 historic, 3 new of which 1 was a reinfection) |
| Treatment starts | 5 | 2 awaiting meds collection who are being assertively engaged |

High Intensity Test and Treat (HITT) Events

Dorset HITT during European Testing Week, 22nd - 29th November 2021

The main highlight of this week was the success of our Hep C U Later funded Find a Friend scheme. Jane from Exchange Supplies led on this initiative and over 45 of the people tested were recruited via her and her networks. It is worth noting that 41 of these people had previously refused testing.

This scheme is continuing and we are utilising the NSP Direct postal dried blood spot testing for those who we cannot engage to come to the van.

Please view the full report of the week here -



Data

The vans have been out for a total 48 days this quarter.

| October | November | December |
|---------|----------|----------|
| 14 | 19 | 15 |

All of the van activity from the start to date has now been uploaded into the Illy Carepath patient database. This ensures consistency of data across the large geographical region and the 30 key stakeholders and partner organisations. The Data and Engagement Lead has led on this work. They have communicated with all stakeholders including patients, organised Illy training and worked on migrating historic data into Illy.

In year 2 of the project, the dashboards will be further developed to include treatment start information and track when SVR's are due. This data is not routinely collected via NDTMS systems and is already proving to be a resource intensive exercise. To counter this we now have a monthly meeting with the ODN Coordinators to cross reference patient referrals and treatment starts. From initial analysis, 47 van patients have started treatment in this quarter and we will be working on compiling full treatment data over the next quarter and into year 2.

Along with this, we will be using the system to track prevalence via new and historic RNA+ and mapping postcodes. This will enable us to target resources and monitor prevalence and reinfections. Out of the 32 diagnoses this quarter, there are 9 re-treatments needed. Again, this is an area to be further reported on in the coming months. We also plan to differentiate between reasons for Cepheid tests and expand the testing information to include DBST and venous bloods.

The vans have also carried out 27 needle exchange transactions and have taken in 200 'litre bins' of used equipment. We are working closely with Exchange Supplies to ensure full needle exchange coverage and access to high quality information and peer support via our new 'Find a Friend' Lead Jane.

In addition to this, in 2021 the vans have been used to complete 208 surveys for the UKHSA Unlinked Anonymous Survey of People Who Inject Drugs across 4 different centres.

HCUL Clinical Vans: Activity Report All Activity

HEP C U Later

Individuals Seen

1012

Total Contacts

1699

Total Tests

1012

Antibody Tests

325

Total Cepheid

361


RNA Positive

110

RNA Negative


251

Patients Seen by Month



Gender

● Male ● Female



Cepheid Detected

110


Referrals to Hep C Treatment

110

Naloxone

13

Hep C Tests Carried Out



Age and Gender

● Female ● Male



HCUL Clinical Vans: Activity Report Wessex Van - 12 months

HEP C U Later

Individuals Seen

808

Total Contacts

1400

Total Tests

808

Antibody Tests

211

Total Cepheid

268


RNA Positive

82

RNA Negative


186

Patients Seen by Month



Gender

● Male ● Female



Cepheid Detected

82


Referrals to Hep C Treatment

82

Naloxone

13

Hep C Tests Carried Out



Age and Gender

● Female ● Male



HCUL Clinical Vans: Activity Report Dorset Van - 12 months

HEP C
U Later

Individuals Seen

206

Total Contacts

299

Total Tests

206

Antibody Tests

116

Total Cepheid

93

RNA Positive


28

RNA Negative

65


Patients Seen by Month

Year ● 2021 ● 2022



Gender

● Male ● Female



Cepheid Detected

28

Referrals to Hep C Treatment


28

Naloxone

13

Hep C Tests Carried Out

Year ● 2021 ● 2022



Age and Gender

● Female ● Male



HCUL Clinical Vans: Activity Report

Quarter 3

HEP C
U Later

Individuals Seen

326

Total Contacts

663

Total Tests

326

Antibody Tests

89

Total Cepheid

116


RNA Positive

32

RNA Negative


84

Patients Seen by Month



Gender

● Male ● Female



Cepheid Detected

32


Referrals to Hep C Treatment

32

Naloxone

3

Hep C Tests Carried Out



Age and Gender

● Female ● Male



Wessex Van : Activity Report Quarter 3

HEP C U Later

Individuals Seen

220

Total Contacts

553

Total Tests

220

Antibody Tests

23

Total Cepheid

76


RNA Positive

22

RNA Negative


54

Patients Seen by Month



Gender

● Male ● Female



Cepheid Detected

22


Referrals to Hep C Treatment

22

Naloxone


3

Hep C Tests Carried Out



Age and Gender

● Female ● Male



Dorset Van : Activity Report Quarter 3

HEP C U Later

Individuals Seen

106

Total Contacts

110

Total Tests

106

Antibody Tests

66

Total Cepheid

40


RNA Positive

10


RNA Negative

30

Patients Seen by Month




Hep C Tests Carried Out



Gender

● Male ● Female



Cepheid Detected

10

Referrals to Hep C Treatment


10

Naloxone

1

Age and Gender

● Female ● Male



Stakeholder Feedback

“The Wessex clinical vans have been invaluable in allowing us to seek post treatment results and assessing new patients reluctant to have treatment . Truly Grateful” - *Jenna Wooding*

“The van has been instrumental in reaching the most vulnerable and difficult to reach patients. Whilst the van itself facilitates this outreach, the hard work of the staff coordinating the running of these clinics deserves special mention as this requires a great deal of dedication and preliminary engagement by the community recovery teams. The coordinated approach between hospital and community services is key to engaging and offering care to these patients”. *Karen Gamble, Hepatology Nurse*

“I would like to say that I found working with the Wessex Hep C Van an absolutely great success. The amount of clients that were tested overall was amazing and I am hoping to be working with the team again this year. Sean Caddy and the Hep C Trust people were efficient and friendly and always happy to help in any way possible to make the time we had as successful as they could. I look forward to our next venture in this new year”. *Arlene Jacques, Turning Point*

“The van is simply amazing!!! It’s a game changer, we now have great opportunities for multi agency work targeting at risk populations away from core services. #findingthemissingmillions”. *Peter Hawley, CGL Hep C Coordinator*

“The Wessex Clinical Van has quickly become an effective and welcomed additional intervention in our work to eliminate HCV. It is a prime example of collaborative, joint working approaches taking evidence based, thoughtful and flexible interventions to where people need them”. *Colin McAllister, Senior Public Health Practitioner*

Stakeholder Feedback

“The Wessex Clinical Van has been invaluable to our ODN . The collaboration between all of the services involved has established an excellent pathway for reaching our mutual goal of HCV Elimination . Through this project we have managed to test and treat patients that we have not managed to engage in our other outreach settings . We have also managed to re engage with patients that were lost to follow up which is vital so as we can monitor treatment success and re infection rates . Going forward I cannot imagine how we will achieve elimination without the use of the van”. *Rebecca Robbins, Hepatology Nurse Specialist*

“Working alongside the Hep C U Later project has not only been productive, but always a pleasure. The van provision has allowed the Hep C Trust peers to work collaboratively with all the important stakeholders across multiple sites in flexible and creative ways, without the boundaries of physical buildings and set services. This has facilitated awareness raising, testing and treatment in a variety of locations in rural Dorset and has been an important tool in reaching the underserved. The combined passion of the dedicated Hep C U Later and Hep C Trust staff and volunteers has made a real difference in the lives of many people and continues to pave the way towards Hepatitis C elimination across the Wessex ODN”. *Miriam Jassey, Hep C Trust Regional Manager*

Patient Feedback

“This service is incredible. I haven’t been tested in years because I don’t have any veins and it is so much hassle. The fact that you came to my house and used your machine without needing to take bloods from my vein is one thing but to tell me my I don’t have Hep C on the same day is out of this world. When I used to go to hospital it would take weeks to get the results. Thank you so much it’s such a worry off my mind”.

Incredible service | Care Opinion

“I just wanted to message you and say thank you to Sean so much for all your help, I hope that you are well. You have been amazing and changed my life for the better and yesterday afternoon was the best news I’ve had for such a long time thank you so much”.

The Health Bus | Care Opinion

Case Study

“My name is Lindsay and I wanted to share my experience with the Wessex Clinical Van service. I have been a long-term service user, having first entered drug treatment services in 2013 for support with cannabis use. I had periods of recovery and then in 2019, I re-entered drug treatment for heroin use. I was tested regularly for hepatitis C but was always negative.



In May 2021, I was retested and was then told I was positive. I was shocked and very distressed about this, I had limited knowledge of hepatitis C or treatments that would be available to me. The Wessex Clinical Van staff supported me every step of the way, I saw them regularly to have pre-treatment tests done and I started treatment in August 2021. I am due to get my SVR done in February 2022.



My experience of the van has been incredible, it enabled me to be diagnosed & treated in a safe space with ongoing support. I don't think I would have undertaken and completed treatment if it wasn't for this provision. I certainly would not have been able to get to the hospital. This service and the staff inspired me so much that in December 2021, I undertook The Hepatitis C Trust peer mentor training and am now volunteering alongside the van”.

Summary

The Wessex Clinical Vans continue to achieve great outcomes through a variety of initiatives such as high intensity test and treat events, pharmacy days and regular outreach clinics.

The van has been used to carry out fibro scans and liver assessments, as well as providing peer support, naloxone, needle exchange and health care referrals. We are now carrying out SVR's on people who have been diagnosed and treated solely on the van.

We continue to make new diagnosis and reach people who are not engaged with services. We are identifying reinfections promptly and are able to actively engage with these patients, providing needle exchange equipment, peer support and other interventions with the aim of reducing reinfection and enhancing treatment compliance.

Funding and plans for 2022-2024

The proposed funding for the van has been added to the ODN Financial information.